Skip to content

Alto Neuroscience ANRO Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$55K-145%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$0-100%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
-$4K-129%
IAR
Integra LifeSciencesIART
-$90K+81.8%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-$334K
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,358%
Enterprise value$630.81M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's gain/loss on asset sales?
Alto Neuroscience (ANRO) reported gain/loss on asset sales of -$9K in Q1 2026.
How has Alto Neuroscience's gain/loss on asset sales changed year-over-year?
Alto Neuroscience's gain/loss on asset sales increased by 78.0% year-over-year, from -$41K to -$9K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.